




Figure S1: Establishment of mixed chimeras so that both donor and recipient-derived Foxp3^+ cells can be depleted or only donor or recipient-derived Foxp3^+ cells can be retained after DT treatment. B6. Foxp3DTR female mice homozygous for the DTR gene were crossed with DBA/2 male mice to obtain F1 generation. F1 mice were used as bone-marrow donors. Three different types of DTR-expressing recipients were created, represented as Groups A, B, and C. Long and short bars represent X and Y chromosomes, respectively. Green boxes represent the '*Foxp3DTR*' gene.




C pre DT 2 d post DT 9 d post DT 16 d post DT 23 d post DT 30 d post DT



D pre DT 2 d post DT 9 d post DT 16 d post DT 23 d post DT 30 d post DT



E pre DT 2 d post DT 9 d post DT 16 d post DT 23 d post DT 30 d post DT






Figure S2 Transient changes in the levels of lymphocyte subsets in the peripheral blood (PBL) following DT treatment. (A-E) PBL were collected at the indicated time points and co-stained with anti-H-2D^d (donor MHC class I) and anti-CD3 (A), anti-CD4 (B), anti-CD8 (C), anti-CD19 (D), or anti-CD49b (E). Inset shows the percentage of events in PBL in each quadrant. (F) Histograms show CD3 staining within the recipient or donor CD49b⁺ subpopulation. Data were obtained pre-DT and 9 days post DT treatment from each group.




Figure S3 Immunohistochemical staining of DBA/2 cardiac allografts from each recipient. DBA/2 cardiac allografts from each recipient were stained with anti-CD3 (A), anti-B220 (B), and anti-Ly49g2 (C). Original magnification for each image is 100x. The areas highlighted in the small boxes in the left panels (100x) are shown in the right panels at a magnification of 400x.

Table S1 Multilineage mixed chimerism in PBL (12 w after BMT) (% in the whole PBL)

	Group A		Group B		Group C	
	Recipient	Donor	Recipient	Donor	Recipient	Donor
Lymphocytes	24.9 ± 15.5	75.1 ± 15.7	19.5 ± 5.8	80.5 ± 5.8	35.7 ± 10.1	64.3 ± 10.1
CD19 ⁺	14.5 ± 13.5	56.5 ± 14.9	7.3 ± 3.3	48.4 ± 11.4	22.2 ± 6.2	50.9 ± 6.2
CD3 ⁺	7.9 ± 4.7	8.9 ± 3.6	6.9 ± 2.0	19.3 ± 8.2	10.0 ± 4.2	7.4 ± 4.5
CD4 ⁺	5.6 ± 3.1	5.1 ± 2.3	3.5 ± 1.4	13.5 ± 6.4	6.8 ± 2.3	4.4 ± 3.6
CD8 ⁺	2.3 ± 1.2	2.6 ± 1.7	2.7 ± 1.2	4.7 ± 1.6	4.0 ± 2.3	2.3 ± 0.4
Foxp3 ⁺	0.6 ± 0.2	0.4 ± 0.2	0.4 ± 0.1	1.5 ± 0.6	0.8 ± 0.1	0.6 ± 0.1
CD11c ⁺	1.6 ± 0.9	4.1 ± 1.2	0.3 ± 0.1	1.6 ± 0.2	0.9 ± 0.4	2.4 ± 0.6
CD49b ⁺	1.0 ± 0.5	2.0 ± 1.5	0.9 ± 0.2	5.0 ± 2.6	1.8 ± 0.4	4.0 ± 0.5

*Numbers reflect the percentages of each cell type within the whole peripheral blood lymphocytes.

Results represent mean values ± s.e.m. of 12, 6, and 5 recipients in Groups A, B, and C, respectively.

Table S2 Heterogeneity of the outcome of allograft rejection

	Acceptance of heart allograft	Rejection of heart allograft
Acceptance of skin allograft	1	1
Rejection of skin allograft	2	8